Clinical Psychopharmacology and Neuroscience 2018; 16(3): 253-261
Different Endocrine Effects of an Evening Dose of Amitriptyline, Escitalopram, and Placebo in Healthy Participants
Lukas Frase1, John Peter Doerr1, Bernd Feige1, Maria Rechenbach1, Bernd L. Fiebich1, Dieter Riemann1, Christoph Nissen1,2,3, and Ulrich Voderholzer1,4
1Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine - University of Freiburg, Freiburg, Germany, 2University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland, 3Neuroscience Center, University of Bern, Bern, Switzerland, 4Schön Klinik Roseneck, Prien, Germany
Correspondence to: Ulrich Voderholzer, MD, Schön Klinik Roseneck, Am Roseneck 6, 83209 Prien am Chiemsee, Germany, Tel: +49-8051-68-100102, Fax: +49-8051-68-100103, E-mail:, ORCID: Christoph Nissen, MD, University Hospital of Psychiatry and Psychotherapy, Bolligenstrasse 111, 3000 Bern 60, Switzerland, Tel: +41-31-930-91-11, Fax: +41-31-930-94-04, E-mail:, ORCID:
Received: March 27, 2017; Revised: July 7, 2017; Accepted: July 10, 2017; Published online: August 31, 2018.
© The Korean College of Neuropsychopharmacology. All rights reserved.

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


The primary aim of this study was to further characterize the acute effects of amitriptyline (AMI) and escitalopram (ESC) on serum levels of ghrelin, leptin, cortisol and prolactin in healthy humans.


Eleven healthy male participants received a single dose of AMI 75 mg, ESC 10 mg, or placebo (PLA) at 9:00 PM in a double blind, randomized, controlled, repeated measures study separated by one week. Fasting morning serum levels (7:00 AM) of ghrelin, leptin, cortisol and prolactin were assessed.


A repeated measures multivariate analysis of variance revealed a significant main effect for the factor condition (AMI, ESC, PLA). Subsequent univariate analyses demonstrated significant condition effects for ghrelin and cortisol. Post-hoc analyses demonstrated a significant reduction of ghrelin levels after AMI in comparison to PLA, and a significant reduction of cortisol levels after AMI in comparison to both ESC and PLA. Other contrasts did not reach statistical significance.


Administration of a single dose of AMI, but not of ESC, leads to a significant reduction in morning serum ghrelin and cortisol levels. No effects on leptin and prolactin levels were observed. The differential impact of AMI and ESC on hormones might contribute to different adverse effect profiles of both substances.

Keywords: Ghrelin, Leptin, Prolactin, Cortisol, Weight gain, Adverse effects

Right now, up to 121 million people worldwide suffer from major depressive disorder (MDD; World Health Organization, 2005). The prevalence is rising and by 2020 MDD is expected to represent the second most prevalent disorder in the world.1) In Germany, citalopram and its S-enantiomer escitalopram (ESC) are the most widely prescribed selective serotonin reuptake inhibitor (SSRI), while amitriptyline (AMI) is the most common tricyclic antidepressant.2) In spite of being effective and, in most cases, well-tolerated, several limiting adverse effects have been described. While tricyclic antidepressants frequently induce weight gain and daytime sleepiness, SSRI can reduce food intake by suppressing hunger and enhancing satiety in humans during the first weeks of treatment.3) Furthermore a disrupt in sexual functioning is often observed in patients taking SSRI.4) Weight gain and loss of sexual functioning have been proposed to be, at least in part, mediated by endocrine systems.

In the brain, the hypothalamus integrates various peripheral signals and sends efferences to the pituary gland. There, metabolic and sexual functions are controlled directly and release hormones regulate subsequent glands, such as the adrenal glands for peripheral stress regulation (hypothalamic-pituitary-adrenal axis, HPA). For food intake, the antagonistic hormones ghrelin and leptin have been identified as important hypothalamic modulators.5) However, the exact mechanisms of the described adverse effects remain to be further investigated.

Ghrelin is a 28-amino acid peptide hormone mainly secreted by stomach cells after meals. Peripherally acylated ghrelin binds at the growth hormone secretagogue receptor in the hypothalamus where it activates a second messenger pathway triggering food intake.6) In addition, smaller amounts of ghrelin can be found directly in the hypothalamus. It is thought to act as a mediator of different pathways involving reward and motivation, stress, anxiety, MDD and possibly sleep regulation.7,8)

Leptin, a 16-kDa protein, is released by white adipocytes and actively transported through the blood-brain barrier via a specific receptor mainly in the hippocampus and near the hypothalamic arcuate nucleus.9) Two different neural cell groups in the hypothalamus are targeted. Here, information about energy status is integrated to this important regulatory brain region.10) Leptin has been proposed to act as an antagonist to ghrelin and mainly suppresses food intake,5) but might have additional effects on other regulatory systems.11)

Cortisol, a steroid hormone produced in humans by the adrenal cortex,12) acts as a peripheral endpoint of the HPA axis. Cortisol levels are elevated in patients with insomnia or MDD.13)

Prolactin, also known as luteotropic hormone, is mostly noted for its influence on mammalian milk production. Symptomatic hyperprolactinemia, a common adverse effect of different antidepressive medications, can result in galactorrhea and erectile dysfunction.14,15) In addition, prolactin has been linked to various different systems, including growth and development, brain and behavior, and immune regulation.16)

Only few studies have centered on the effects of AMI on endocrine levels during pharmacological treatment. For ghrelin serum levels, an increase in 28 healthy volunteers has been detected following one week of administration.17) In addition, an increase of leptin serum levels during AMI treatment was reported in patients with MDD.18) However conflicting data exists, as unchanged leptin levels in 12 inpatients with major depression have been determined during six weeks of AMI treatment.19) In addition, a reduction of cortisol levels has been shown in AMI responders following 25 days of treatment.20) So far, no study has investigated the effects of AMI on prolactin serum levels.

Other studies have analyzed the effects of ESC and citalopram. Patients with MDD showed reduced ghrelin serum levels prior to treatment with citalopram, without normalization following treatment.21) Forty-four out-patients with binge eating disorder received either ESC or placebo (PLA) in a 12-week, double-blind, flexible dose study reporting no changes in ghrelin or leptin levels.22) No changes in leptin serum levels have been observed following 8 weeks of citalopram treatment in 14 depressed and 18 non-depressed women.23) In contrast, forty patients with premature ejaculation, a syndrome recently linked to increased leptin serum levels, demonstrated a reduction in serum levels after eight weeks of citalopram treatment.24) An acute increase of cortisol serum levels in healthy volunteers has been observed following oral citalopram administration.25,26) In addition, an immediate increase of cortisol and prolactin serum levels has been reported following a 20 mg citalopram infusion.27)

This study represents the first double-blind, randomized, repeated measures, PLA-controlled trial directly comparing the short term effects of the two anti-depressants AMI and ESC on the serum levels of ghrelin, leptin, cortisol and prolactin in healthy participants.



Fourteen healthy male volunteers were recruited via personal contact for a double-blind, randomized, repeated measures, PLA-controlled trial on the impact of AMI and ESC on polysomnographic sleep and endocrinological parameters. Polysomnographic findings from this trial have already been published.28) Two participants were excluded after the adaptation night (atrio-ventricular block, technical recording failure). One participant was excluded due to protocol violation (shift working), leading to a total of 11 analyzed participants for the current analysis (24.7±2.4 years; age range, 20–32 years; body mass index, 22.5±1.4 kg/m2).

The study had been approved by the local ethics committee and registered in the German Register for Clinical Studies (, DRKS00000160). Participants provided written informed consent prior to the onset of the study. All participants underwent a thorough screening process by an experienced clinician, including a physical examination, a semi-structured interview for psychiatric disorders or substance use, and tests for specific laboratory parameters (thyroid, renal and liver function, hematology, biochemistry, electroencephalography [EEG] and electrocardiogram [ECG], urine drug screening). Polysomnography was used to ensure the absence of a respiratory (apnea-hypopnea-index, <5/hour) or movement-related sleep disorder (periodic limb movements with arousal, <5/hour). Additional exclusion criteria included any clinically relevant disorder, unstable sleep patterns, participation in any other clinical trial within the last month, and intake of any medication within 2 weeks prior to and during the study. All participants received financial remuneration.

Study Design

All participants underwent a within-subject, double-blind, PLA-controlled, randomized, repeated-measures protocol comprising three blocks with polysomnographic monitoring from 11:00 PM to 7:00 AM at the sleep laboratory of the University Medical Center Freiburg (Fig. 1).

Each block consisted of one adaptation night followed by one experimental night. The blocks were separated by at least 7 days. At 9:00 PM prior to the experimental nights, a single dose of either 75 mg AMI, 10 mg ESC or PLA was orally administered. Medications were matching white capsules provided and randomized by the pharmacy of the Johannes Gutenberg-University of Mainz. Daytime sleepiness was measured by the multiple sleep latency test (MSLT). Daytime alertness and vigilance was measured by neurocognitive tasks (Testbatterie zur Aufmerksamkeitsleistung, TAP; and D2 concentration test).29,30) Blood samples were collected at 7:15 AM following an overnight fast and immediately stored at −70°C. Immediately after completion of the study, serum ghrelin, leptin, cortisol and prolactin levels were analyzed.

Endocrine Analyses

Serum ghrelin and leptin levels were measured at the research laboratory of the Centre for Mental Disorders, University Medical Center Freiburg (ghrelin: [Human] EIA-Kit from Phoenix Pharmaceutical Cat. No. EK-031- 30, intra-assay error: <5%, inter-assay error: <14%; leptin: [Human] ELISA-Kit from DRG GmbH, Marburg Cat. No. EIA-2395, intra-assay error: <7%, inter-assay error: <12%). Levels were determined twice and mean values were further analyzed. Serum levels of cortisol and prolactin were investigated at the central laboratory of the University Medical Center Freiburg (cortisol: Electro-chemiluminescence Immunoassay “ECLIA”, Modular Analytics E170, Elecsys 2010 and cobas e 411 and cobas e 601 as Immunoassay Analyzers; prolactin: Electro-chemiluminescence Immunoassay “ECLIA”, Modular Analytics E170, Elecsys 2010 and cobas e 411 and cobas e 601 as Immunoassay Analyzers).

Statistical Analysis

Early morning serum levels of leptin, ghrelin, prolactin and cortisol were defined as primary outcome parameters. Descriptive values are given as means and standard deviations. To test for differences in endocrine responses to the medication, a repeated-measures multivariate analysis of variance (rmMANOVA) with the within-subject factor condition (ESC, AMI, PLA) was conducted. Post-hoc contrasts were calculated for significant main effects. For the estimation of effect sizes, partial eta square (pETA2) values were calculated (low, <0.06; medium, ≥0.06 and <0.14; large, ≥0.14). The level of significance was set at p<0.05 (two-tailed). Assuming an a priori test power of 80%, the selected sample size of 15 participants was sufficient to detect medium to large effect sizes for the primary analysis. All analyses were conducted using the statistical software IBM SPSS Statistics, version 21 (IBM Co., Armonk, NY, USA), and R version 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria).


Morning Levels of Ghrelin, Leptin, Cortisol, and Prolactin

The morning levels of ghrelin, leptin, cortisol and prolactin for each condition are listed in Table 1. The rmMANOVA indicated a highly significant main effect for the factor condition (F=3.3, p=0.006). Subsequent univariate analyses demonstrated significant condition effects for ghrelin and cortisol. Post-hoc tests revealed a significant reduction of ghrelin levels after administration of AMI compared to PLA, and a significant reduction of cortisol levels after administration of AMI compared to both PLA and ESC. No significant effects on leptin or prolactin were detected. The main findings are visualized in Figure 2.

Exploratory Correlation of Endocrine Changes with Sleep and Vigilance

Assuming that early morning serum concentrations correlates with hormone concentrations during the preceding night and to further explore possible relationships of endocrine changes on polysomnographic nighttime sleep, daytime sleepiness (MSLT) and attention (TAP, D2), two linear regression models were employed with these dependent variables on already published polysomnographic findings from this trial.28) The intra- and interindividual influences on sleep and daytime performance are listed in Table 2.

The first multiple regression analysis (R module stats::lm) related ghrelin, leptin, cortisol and prolactin serum levels to the dependent variables across subjects within the PLA condition to determine the absolute individual influence of ghrelin, leptin, cortisol and prolactin serum levels on sleep and daytime performance (interin-dividual effects). The analyses demonstrated a significant positive relationship between morning ghrelin serum levels and wake periods in the preceding night. No other correlations were found.

The second analysis utilized a linear mixed-effects model (R module nlme::lme) with the within-subject factor condition (ESC, AMI, PLA) and ghrelin, leptin, cortisol and prolactin serum levels as covariates to disentangle direct pharmacological influences on sleep and daytime sleepiness and performance from possible, indirect effects through changes in ghrelin, leptin, cortisol or prolactin serum levels (intraindividual effects). Reported beta values of the linear model are differences, relative to PLA by the factor condition and regression coefficients for the serum levels. As already reported by Doerr et al.,28) ESC led to a significantly lower total sleep time (TST) and sleep efficiency (SE) compared to AMI. Wake time after sleep onset decreased after AMI compared to PLA and ESC and increased after ESC compared to PLA and AMI. In addition, both substances significantly suppressed rapid eye movement sleep (REM) and increased REM latency (REML). Sleep stage 2 increased following AMI and was lower under ESC than PLA and AMI. During the next day, AMI decreased daytime sleep onset latency (SOL) and WE (WE) in the multiple sleep latency test (MSLT) and led to longer reaction times in an alertness task (TAP) and fewer correctly marked letters in the ‘d2 concentration test’ (D2) compared to PLA and ESC, while ESC increased SOL and WE and slightly improved performance tasks compared to AMI, but not PLA.28)

The intraindividual regression model showed an increased amount of stage 2 sleep, reduced amount of REM sleep, increased REML as well as reduced MSLT SOL and WE and reduced D2 performance after AMI. ESC reduced TST and SE, increased wake periods, decreased REM sleep, increased REML and decreased REM density.

Larger ghrelin serum level were found to be related to increased SOL and number of wake periods as well as MSLT WE. Larger leptin level were only related to an increased amount of REM sleep. Prolactin and cortisol serum levels were not significantly related to sleep and daytime performance parameters.


The results of this study indicate that a single dose of AMI reduces early morning ghrelin and cortisol serum levels. More specifically, a single evening dose of 75-mg AMI decreased ghrelin serum levels in the morning compared to PLA and cortisol serum levels in the morning compared to ESC and PLA in healthy young men. Those results were not found at ESC.

The observed reduction of ghrelin serum levels after a single dose of AMI differs from the reported increase following long-term administration.17) Thus, our finding complements the described increase after long term treatment in the literature. Increased food intake and weight-gain are common side effects of AMI. It remains to be further determined whether the acute reduction of serum ghrelin levels observed in the current study, after administration of AMI, can mediate this weight gain. With regard to potential mechanisms, anticholinergic properties of AMI might mediate the acute reduction of ghrelin, since circulating ghrelin levels in humans are reduced by cholinergic antagonists.31) As a complementary explanation for an AMI-induced weight gain, it is to note that AMI acts antagonistically on the histamine H1 receptor in rats, another pathway with high importance for the regulation of body weight.32,33) Yet it should be noted that the complex regulation of body weight remains to be fully delineated. Despite the acute promotion of food intake, ghrelin serum levels are, for example, inversely related to the body mass index.34)

The current study is also the first to report reduced cortisol levels after AMI. It thereby complements reports on reduced cortisol levels after the sedating antidepressants trazodone and mirtazapine in healthy humans.35,36) This acute reduction of daytime cortisol levels might play an independent role in the described side effects of weight gain. In contrast to AMI, a single-dose of ESC in the evening showed no significant impact on morning hormone serum levels. This observation corroborates studies describing no effect on leptin serum levels after treatment with citalopram or ESC.22,23) It is possible that a reduction can only be observed in populations with increased leptin levels, such as described for premature ejaculation.24) This would, at least indirectly, be in line with animal studies, in which a novel serotonin-reuptake inhibitor 3-me-thoxy-N-p-tolylquinoxalin-2-carboxamide (QCM-4) attenuated HPA axis hyperactivity in an obese mouse model of MDD by reversing increased plasma leptin.37) It is of further interest that no immediate effect on prolactin levels were detected despite frequent sexual dysfunctions under treatment with ESC. The underlying mechanisms remain to be fully understood. It might be that alterations on prolactin levels emerge only after long-term treatment with ESC. Alternatively, adverse effects of ESC on sexual functioning might be mediated by non-endocrinological effects, such as neuronal nitrogen monoxide.38)

In an exploratory approach we referred to already published data on the direct impact of AMI and ESC on polysomnographic nighttime sleep, daytime sleepiness (MSLT) and attention.28)

As our main finding here, individually higher morning ghrelin serum levels were related to wake periods in the preceding night during the PLA condition. In addition, ghrelin was associated with the amount of wake periods and sleep onset latency as well as with WE in the MSLT independently of ESC/AMI in the experimental nights. The strong decrease in daytime WE reported for AMI could therefore be partially driven or enhanced by modulation of the ghrelin system in addition to an ongoing sedating antihistaminic effect of AMI due to its long half-value period of 10 to 28 hours. However, as the study design cannot identify causal relationships, it is also possible that an enhancement of wake periods during the night leads to changes in ghrelin serum levels. This alternative explanation would be supported by findings of reduced leptin and elevated ghrelin serum levels following short sleep duration.39)

In addition, higher individual leptin levels were negatively related to REM sleep. This finding might represent a REM sleep suppressing effect of leptin, possibly through a direct interaction with the serotonergic system, which could enhance direct pharmacological REM suppression.40,41) It is to note though, that these interpretations are only based on exploratory analyses.

The reported increased sleep continuity, suppressed REM sleep, and impaired daytime vigilance and performance following AMI are, according to the employed simultaneous regression model, to be regarded largely independent of the endocrine systems we considered, i.e. they are not mediated by changes in ghrelin, leptin, cortisol or prolactin. This appears to be true as well for the decreased sleep continuity, suppressed REM sleep and improved daytime sleepiness and performance following ESC.28) The effects of AMI and ESC on REM sleep are well known and mainly induced by noradrenergic/serotoninergic and anticholinergic effects.4244)

It is to note, though, that at least cortisol undergoes a circadian rhythm with differing serum levels. Twenty-four hour-sampling would be needed to further delineate the time-course of serum hormone levels. It is to note that we investigated serum levels 10 hours after medication intake. Early onset effects might have been missed as well as enduring long-time changes. Another limitation of the current analysis is sample size. However, we used a well-controlled, repeated measures design and observed large effect sizes for the impact of AMI on ghrelin and cortisol levels.

A single-dose of AMI in the evening decreased early morning levels of ghrelin and cortisol, but did not affect leptin or prolactin levels. ESC did not to have acute effects on the described endocrine systems. These findings on acute effects complement those on long-term administration and contribute to further disentangle the acute and long-term clinical effects of the described anti-depressants. In addition, individually higher ghrelin serum levels were related to increased wake periods and higher leptin serum levels to reduced REM sleep periods in the preceding night. The relationship between sleep and daytime performance on one hand and early morning ghrelin and leptin serum levels on the other hand warrants further examination.


This study was sposored by Investigator initiated trial (UV) supported by Lundbeck, Germany. CN has received speaker honoraria from Servier. DR has received speaker honoraria from Abbvie. All of the other authors declare no conflicts of interest. The manuscript includes parts of the MD thesis of M. Reichenbach. The authors thank F. Petzold for help in data acquisition.

Supplementary Information
Fig. 1. Study design. Eleven healthy male participants underwent a within-subject repeated-measures protocol comprising 3 blocks with polysomnographic monitoring from 11:00 PM to 07:00 AM separated by one week. Either 10 mg escitalopram (ESC), 75 mg amitryptilin (AMI) or placebo (PLA) were orally administered at 09:00 PM. Blood samples were collected between 7:00 and 7:30 AM shortly after awakening and tested for ghrelin, leptin, prolactin and cortisol serum levels.
Fig. 2. Morning levels of ghrelin, leptin, prolactin and cortisol after evening administration of 10 mg escitalopram (ESC), 75 mg amitryptilin (AMI) or placebo (PLA). A significant within-subject condition effect was detected for ghrelin and cortisol levels. Post-hoc tests revealed significantly lower levels of ghrelin following AMI compared to PLA and of cortisol following AMI compared to PLA and ESC. Bars indicate the standard error of the mean; *Significant main effect for condition.

Early morning serum levels of ghrelin, leptin, prolactin and cortisol after 10 mg ESC, 75 mg AMI or PLA

Variable ESC AMI PLA F p pETA2
Ghrelin (pg/ml) 198.6±39.9 146.5±82.6 217.8±109.3 4.2 0.031* 0.294
Leptin (ng/ml) 6.4±3.3 6.7±3.5 7.6±4.6 1.2 0.323 0.107
Prolactin (mIU/L) 355.1±151.6 301.0±158.4 339.5±165.3 1.1 0.338 0.103
Cortisol (nmol/L) 636.0±120.3 515.5±128.8 608.8±124.0 5.9 0.010*, 0.372

Values are presented as mean±standard deviation.

ESC, escitalopram; AMI, amitriptyline; PLA, placebo; ESC, escitalopram; pETA2, partial eta square.

ANOVAs with the factor condition (ESCIT, AMI, PLA).

Significant contrast AMI vs. PLC;

significant ESCIT vs. AMI.

Inter- and intraindividual relationships of endocrine changes with sleep, daytime sleepiness and vigilance parameters

Parameter Interindividual effects (placebo) Intraindividual effects

Ghrelin Leptin Prolactin Cortisol ESC AMI Ghrelin Leptin Prolactin Cortisol

Beta p Beta p Beta p Beta p Beta p Beta p Beta p Beta p Beta p Beta p
TST −0.18 0.176 0.85 0.795 0.02 0.836 0.06 0.649 −45.76 0.005* 3.22 0.839 −0.0 0.232 0.07 0.972 −0.2 0.750 −0.03 0.571
SEI −0.04 0.187 0.03 0.964 0.00 0.926 0.01 0.693 −9.28 0.004* 1.40 0.658 −0.02 0.192 −0.05 0.896 0.00 0.713 −0.01 0.526
SOL 0.15 0.053 0.63 0.721 0.03 0.552 −0.09 0.239 1.74 0.762 −4.69 0.484 0.08 0.047* 10.23 0.177 0.02 0.383 0.01 0.672
WASO 0.05 0.386 −0.42 0.756 −0.02 0.670 0.02 0.704 41.40 0.003* 0.17 0.990 0.04 0.516 −0.68 0.658 0.01 0.894 0.03 0.611
Wake periods 0.06 0.003* 0.11 0.756 −0.02 0.056 0.01 0.698 6.64 0.086 0.44 0.914 0.06 0.013* −0.69 0.153 −0.02 0.055 0.00 0.850
Wake 0.01 0.315 −0.11 0.744 0.00 0.752 0.00 0.880 9.06 0.003* −0.02 0.995 0.01 0.459 −0.12 0.714 0.00 0.836 0.01 0.600
Stage 1 0.01 0.197 0.09 0.669 0.01 0.066 −0.01 0.426 1.18 0.224 −2.11 0.103 0.01 0.203 −0.23 0.261 0.00 0.970 0.00 0.424
Stage 2 −0.01 0.556 −0.28 0.515 0.00 0.925 0.01 0.669 −3.29 0.243 1.11 0.008* −0.01 0.479 −0.30 0.555 0.00 0.928 0.00 0.876
SWP −0.03 0.083 −0.23 0.551 −0.02 0.136 0.00 0.983 2.74 0.139 3.43 0.164 −0.01 0.648 0.07 0.868 −0.01 0.089 0.00 0.885
REM 0.02 0.159 0.54 0.089 0.01 0.382 0.00 0.877 −9.62 0.000* −1.94 0.000* 0.01 0.280 0.65 0.005* 0.01 0.189 0.00 0.596
REML −0.01 0.955 3.08 0.331 0.07 0.415 0.03 0.796 157.38 0.000* 244.50 0.000* 0.17 0.403 −4.13 0.367 −0.11 0.344 −0.06 0.695
REMD 0.02 0.631 0.62 0.492 0.00 0.989 0.02 0.660 −4.45 0.033* 1.83 0.511 0.02 0.339 0.19 0.696 0.00 0.622 0.01 0.397
MSLT SOL −0.01 0.253 0.04 0.897 0.00 0.602 0.00 0.998 2.16 0.082 −4.77 0.005* −0.01 0.115 0.15 0.519 −0.01 0.252 0.01 0.338
MSLT WE −0.07 0.122 0.11 0.922 −0.04 0.234 0.03 0.460 6.96 0.180 −26.21 0.001* −0.09 0.034* 0.21 0.847 −0.03 0.254 0.04 0.169
TAP −0.05 0.426 0.02 0.607 0.05 0.389 −1.13 0.483 −2.47 0.577 4.32 0.476 −0.02 0.522 0.01 0.729 0.00 0.887 −1.34 0.205
D2 −0.02 0.968 0.05 0.855 0.14 0.695 5.71 0.545 6.97 0.592 −43.03 0.045* −0.15 0.100 −0.08 0.287 −0.05 0.685 −1.33 0.734

ESC, escitalopram; AMI, amitriptyline; TST, total sleep time (min); SEI, sleep efficiency; SOL, sleep onset latency; WASO, wake time after sleep onset; SWP, percentage of slow wave sleep; REM, rapid eye movement sleep; REMD, rapid eye movement density; MSLT SOL, sleep onset latency in the multiple sleep latency test; MSLT WE, wake efficiency in the multiple sleep latency test; TAP, alertness test; D2, D2 concentration test.

Significant correlation.

  1. Gayetot, D, Ansseau, M, and Triffaux, JM (2007). Rev Med Liege. 62, 103-111.
  2. Lohse, MJ, and Müller-Oerlinghausen, B (2015). Psychopharmaka. Arzneiverordnungs-Report 2015: Aktuelle Daten, Kosten, Trends und Kommentare, Schwabe, U, and Paffrath, D, ed. Berlin-Heidelberg: Springer-Verlag, pp. 939-981
  3. Halford, JC, Boyland, EJ, Lawton, CL, Blundell, JE, and Harrold, JA (2011). Serotonergic anti-obesity agents: past experience and future prospects. Drugs. 71, 2247-2255.
    Pubmed CrossRef
  4. Ferguson, JM (2001). SSRI Antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. 3, 22-27.
  5. Kanoski, SE, and Grill, HJ (2017). Hippocampus contributions to food intake control: Mnemonic, neuroanatomical, and endocrine mechanisms. Biol Psychiatry. 81, 748-756.
    Pubmed KoreaMed CrossRef
  6. Meier, U, and Gressner, AM (2004). Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 50, 1511-1525.
    Pubmed CrossRef
  7. Schanze, A, Reulbach, U, Scheuchenzuber, M, Groschl, M, Kornhuber, J, and Kraus, T (2008). Ghrelin and eating disturbances in psychiatric disorders. Neuropsychobiology. 57, 126-130.
    Pubmed CrossRef
  8. Schellekens, H, Finger, BC, Dinan, TG, and Cryan, JF (2012). Ghrelin signalling and obesity: at the interface of stress, mood and food reward. Pharmacol Ther. 135, 316-326.
    Pubmed CrossRef
  9. Price, TO, Farr, SA, Yi, X, Vinogradov, S, Batrakova, E, and Banks, WA (2010). Transport across the blood-brain barrier of pluronic leptin. J Pharmacol Exp Ther. 333, 253-263.
    Pubmed KoreaMed CrossRef
  10. Roubos, EW, Dahmen, M, Kozicz, T, and Xu, L (2012). Leptin and the hypothalamo-pituitary-adrenal stress axis. Gen Comp Endocrinol. 177, 28-36.
    Pubmed CrossRef
  11. Brennan, AM, and Mantzoros, CS (2006). Drug Insight: the role of leptin in human physiology and pathophysiology--emerging clinical applications. Nat Clin Pract Endocrinol Metab. 2, 318-327.
    Pubmed CrossRef
  12. Gorman, LS (2013). The adrenal gland: common disease states and suspected new applications. Clin Lab Sci. 26, 118-125.
  13. Nestler, EJ, Barrot, M, DiLeone, RJ, Eisch, AJ, Gold, SJ, and Monteggia, LM (2002). Neurobiology of depression. Neuron. 34, 13-25.
    Pubmed CrossRef
  14. Camkurt, MA, Gülpamuk, G, Fındiklı, E, and Elve, R (2017). Dose dependent course of hyperprolactinemic and normoprolactinemic galactorrhea induced by venlafaxine. Clin Psychopharmacol Neurosci. 15, 181-183.
    Pubmed KoreaMed CrossRef
  15. Molitch, ME (2008). Drugs and prolactin. Pituitary. 11, 209-218.
    Pubmed CrossRef
  16. Bole-Feysot, C, Goffin, V, Edery, M, Binart, N, and Kelly, PA (1998). Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev. 19, 225-268.
    Pubmed CrossRef
  17. Huang, W, Jiang, SM, Jia, L, You, LQ, Huang, YX, and Gong, YM (2013). Effect of amitriptyline on gastrointestinal function and brain-gut peptides: a double-blind trial. World J Gastroenterol. 19, 4214-4220.
    Pubmed KoreaMed CrossRef
  18. Schilling, C, Gilles, M, Blum, WF, Daseking, E, Colla, M, and Weber-Hamann, B (2013). Leptin plasma concentrations increase during antidepressant treatment with amitriptyline and mirtaza-pine, but not paroxetine and venlafaxine: leptin resistance mediated by antihistaminergic activity?. J Clin Psychopharmacol. 33, 99-103.
    Pubmed CrossRef
  19. Hinze-Selch, D, Schuld, A, Kraus, T, Kühn, M, Uhr, M, and Haack, M (2000). Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology. 23, 13-19.
    Pubmed CrossRef
  20. Deuschle, M, Hamann, B, Meichel, C, Krumm, B, Lederbogen, F, and Kniest, A (2003). Antidepressive treatment with amitriptyline and paroxetine: effects on saliva cortisol concentrations. J Clin Psychopharmacol. 23, 201-205.
    Pubmed CrossRef
  21. Barim, AO, Aydin, S, Colak, R, Dag, E, Deniz, O, and Sahin, I (2009). Ghrelin, paraoxonase and arylesterase levels in depressive patients before and after citalopram treatment. Clin Biochem. 42, 1076-1081.
    Pubmed CrossRef
  22. Guerdjikova, AI, McElroy, SL, Kotwal, R, Welge, JA, Nelson, E, and Lake, K (2008). High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. Hum Psychopharmacol. 23, 1-11.
    Pubmed CrossRef
  23. Kauffman, RP, Castracane, VD, White, DL, Baldock, SD, and Owens, R (2005). Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age. Gynecol Endocrinol. 21, 129-137.
    Pubmed CrossRef
  24. Atmaca, M, Kuloglu, M, Tezcan, E, Semercioz, A, Ustundag, B, and Ayar, A (2002). Serum leptin levels in patients with premature ejaculation. Arch Androl. 48, 345-350.
    Pubmed CrossRef
  25. Schüle, C (2007). Neuroendocrinological mechanisms of actions of antidepressant drugs. J Neuroendocrinol. 19, 213-226.
    Pubmed CrossRef
  26. Hawken, ER, Owen, JA, Hudson, RW, and Delva, NJ (2009). Specific effects of escitalopram on neuroendocrine response. Psychopharmacology (Berl). 207, 27-34.
    Pubmed CrossRef
  27. Seifritz, E, Baumann, P, Müller, MJ, Annen, O, Amey, M, and Hemmeter, U (1996). Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology. 14, 253-263.
    Pubmed CrossRef
  28. Doerr, JP, Spiegelhalder, K, Petzold, F, Feige, B, Hirscher, V, and Kaufmann, R (2010). Impact of escitalopram on nocturnal sleep, day-time sleepiness and performance compared to amitripty-line: a randomized, double-blind, placebo-controlled study in healthy male subjects. Pharmacopsychiatry. 43, 166-173.
    Pubmed CrossRef
  29. Zimmermann, P, and Fimm, B (2007). Testbatterie zur Aufmerksamkeit-sleistung (TAP). Würselen: Psytest
  30. Brickenkamp, R (1994). Test d2 Aufmerksamkeits-Belastungs-Test. Göttingen: Hogrefe Verlag
  31. Broglio, F, Gottero, C, Van Koetsveld, P, Prodam, F, Destefanis, S, and Benso, A (2004). Acetylcholine regulates ghrelin secretion in humans. J Clin Endocrinol Metab. 89, 2429-2433.
    Pubmed CrossRef
  32. Reilly, MA, and Sigg, EB (1982). Suppression of histamine-induced adrenocorticotropic hormone release by antihistamines and antidepressants. J Pharmacol Exp Ther. 222, 583-588.
  33. Jørgensen, EA, Knigge, U, Warberg, J, and Kjaer, A (2007). Histamine and the regulation of body weight. Neuroendocrinology. 86, 210-214.
    Pubmed CrossRef
  34. Cummings, DE (2006). Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav. 89, 71-84.
    Pubmed CrossRef
  35. Monteleone, P (1991). Effects of trazodone on plasma cortisol in normal subjects. A study with drug plasma levels. Neuropsychopharmacology. 5, 61-64.
  36. Laakmann, G, Schüle, C, Baghai, T, and Waldvogel, E (1999). Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology. 24, 769-784.
    Pubmed CrossRef
  37. Kurhe, Y, Mahesh, R, and Devadoss, T (2015). QCM-4, a 5-HT3 receptor antagonist ameliorates plasma HPA axis hyperactivity, leptin resistance and brain oxidative stress in depression and anxiety-like behavior in obese mice. Biochem Biophys Res Commun. 456, 74-79.
    Pubmed CrossRef
  38. Angulo, J, Peiró, C, Sanchez-Ferrer, CF, Gabancho, S, Cuevas, P, and Gupta, S (2001). Differential effects of serotonin reuptake inhibitors on erectile responses, NO-production, and neuronal NO synthase expression in rat corpus cavernosum tissue. Br J Pharmacol. 134, 1190-1194.
    Pubmed KoreaMed CrossRef
  39. Taheri, S, Lin, L, Austin, D, Young, T, and Mignot, E (2004). Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Med. 1, e62.
    Pubmed KoreaMed CrossRef
  40. Calapai, G, Corica, F, Corsonello, A, Sautebin, L, Di Rosa, M, and Campo, GM (1999). Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis. J Clin Invest. 104, 975-982.
    Pubmed KoreaMed CrossRef
  41. Charnay, Y, Cusin, I, Vallet, PG, Muzzin, P, Rohner-Jeanrenaud, F, and Bouras, C (2000). Intracerebroventricular infusion of leptin decreases serotonin transporter binding sites in the frontal cortex of the rat. Neurosci Lett. 283, 89-92.
    Pubmed CrossRef
  42. Nissen, C, Nofzinger, EA, Feige, B, Waldheim, B, Radosa, MP, and Riemann, D (2006). Differential effects of the muscarinic M1 receptor agonist RS-86 and the acetylcholine-esterase inhibitor donepezil on REM sleep regulation in healthy volunteers. Neuropsychopharmacology. 31, 1294-1300.
    Pubmed CrossRef
  43. Broese, M, Riemann, D, Hein, L, and Nissen, C (2012). α-Adrenergic receptor function, arousal and sleep: mechanisms and therapeutic implications. Pharmacopsychiatry. 45, 209-216.
    Pubmed CrossRef
  44. Riemann, D, and Nissen, C (2012). Sleep and psychotropic drugs. The oxford handbook of sleep and sleep disorders, Morin, CM, and Espie, CA, ed. Oxford: Oxford University Press, pp. 190-222

This Article

Close ✕

Cited By Articles

Author ORCID Information

Social Network Service